Synonyms: NE_MS_BL_TreatImm_Siponimod IM_OtherImmun_Siponimod MS_Siponimod

This is just here as a test because I lose it

Term information

hasDefinition

Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 6 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS

importedFrom

http://purl.obolibrary.org/obo/NCIT_C152368

label

Siponimod

uniqueIdentifier

http://purl.bioontology.org/ontology/SNOMEDCT/786997005